Abstract:BACKGROUND AND AIM:This study retrospectively explored the potential association between CK19 expression and efficacy of adjuvant conventional transarterial chemoembolization (TACE) after hepatic resection in patients with hepatocellular carcinoma (HCC) at high risk of recurrence.METHODS:Patients (n = 508) who underwent hepatic resection between January 2012 and December 2017 were enrolled. Overall survival (OS) and recurrence-free survival (RFS) were compared between groups. Survival analysis was performed using the Kaplan-Meier method, and groups were compared using the log-rank test.RESULTS:OS and RFS were worse for CK19-positive patients than for CK19-negative patients, regardless of whether patients were matched on the basis of propensity scores. Among CK19-positive patients in the absence of propensity score matching, TACE was associated with better RFS. Among CK19-negative patients in the absence of propensity matching, TACE was associated with better OS and RFS. Among patients treated with TACE, CK19-positive patients showed worse OS but similar RFS as CK19-negative patients. Multivariate analysis identified the following independent predictors of worse OS: CK19 positivity, no adjuvant TACE, macrovascular invasion, microvascular invasion, tumor size >5 cm, alanine transaminase >80 U/L, and aspartate transaminase >80 U/L. Multivariate analysis identified the following predictors of worse RFS: CK19 positivity, no adjuvant TACE, age ≥60 years, alpha-fetoprotein ≥400 ng/ml, and Barcelona Clinic Liver Cancer stage B/C.CONCLUSION:This study suggests that among HCC patients at high risk of recurrence, adjuvant TACE can significantly prolong OS and RFS of CK19-negative patients, while it may prolong only RFS of CK19-positive patients.RELEVANCE FOR PATIENTS:Not all patients will benefit from adjuvant TACE, therefore, it is necessary to select the best benefit subsets before TACE. By studying the relationship between CK19 expression and TACE benefit, it will be possible to help guide decision-making about adjuvant TACE in HCC patients at high risk of recurrence.

CK19 mRNA expression measured by reverse-transcription polymerase chain reaction (RT-PCR) in the peripheral blood of patients with non-small cell lung cancer treated by chemo-radiation: an independent prognostic factor.

Study on the correlationship between CK19mRNA and CyFRA21-1 in peripheral blood of lung cancer patients

CK19 mRNA expression and its clinical significances in peripheral blood of non-small cell lung cancer patients before definitive chemoradiotherapy

Detection of CK19mRNA in the Peripheral Blood of Lung Cancer Patients by Fluorogenic Quantitative Reverse Transcripition-Polymerase Chain Reaction

CK-19 mRNA-positive cells in peripheral blood predict treatment efficacy and survival in small-cell lung cancer patients

Expression of CK19-mRNA in Cancerous and Paracancerous Tissues and Peripheral Blood of Lung Cancer Patients by Real-time Fluorescent Quantitative RT-PCR and Its Clinical Significance

Detection and quantitation of CK19 mRNA in the peripheral blood and regional lymph nodes of lung cancer patients

Clinical Significance of Expressions of LunX and CK19 Mrna in Peripheral Blood in Lung Cancer

Increased levels of CK19 mRNA in oral squamous cell carcinoma tissue detected by relative quantification with real-time polymerase chain reaction.

RRM1 Gene Expression in Peripheral Blood is Predictive of Shorter Survival in Chinese Patients with Advanced Non-Small-cell Lung Cancer Treated by Gemcitabine and Platinum

Relationship between CK19 mRNA expression in peripheral blood cells and the clinical factors of breast cancer patients with axillary lymph node-negative

First-line Gemcitabine Plus Cisplatin in Nonsmall Cell Lung Cancer Patients.

Detection of Micrometastases of Non-small Cell Lung Cancer by Using CK19 mRNA and LUNX mRNASpecific Reverse Transcription-polymerase Chain Reaction

Study of CK19 mRNA in blood of patients with colorectal cancer

[Detection of CK19 and CEA mRNA expression for the diagnosis of peripheral blood micrometastases in patients with non-small cell lung cancer].

Detection and prognostic significance of micrometastasis in peripheral blood of patients with non-small cell lung cancer treated by chemo-radiation therapy

Quantitative Real-Time RT-PCR Detection for CEA, CK20 and CK19 Mrna in Peripheral Blood of Colorectal Cancer Patients.

[Relative Quantification of Cytokeratin 19 Transcription in Oral Squamous Cell Carcinoma Tissues by Fluorescent Quantitive Real-Time RT-PCR].

Association of CK19 Expression with the Efficacy of Adjuvant Transarterial Chemoembolization after Hepatic Resection in Hepatocellular Carcinoma Patients at High Risk of Recurrence.

The Detection and Its Clinical Significance of Cytokeratin 19 Mrna (CK19 Mrna) in Pelvic Lymph Nodes of Cervical Cancer Patients

Clinical Significance of Preoperative and Postoperativecytokeratin 19messenger RNA Level in Peripheral Blood of Esophageal Cancer Patients